Author:
Chithra J. S.,Asha Nair S.
Reference26 articles.
1. Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C (2005) Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Prev Biomarkers 14:1724–1731. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/16030108
. Accessed on 06 Oct 2017
2. Chaudhry P, Asselin E (2009) Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 16:363–380. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/19190080
. Accessed on 23 July 2014
3. Burke WM, Orr J, Leitao M, Salom E, Gehrig P, Olawaiye AB, Brewer M, Boruta D, Herzog TJ, Shahin FA (2014) SGO clinical practice endometrial cancer Working Group. Endometrial cancer: A review and current management strategies: part II. Gynecol oncol Aug 1, 134(2):393–402
4. Dai D, Wolf DM, Litman ES, White MJ, Leslie KK (2002) Progesterone inhibits human endometrial cancer cell growth and invasiveness: down-regulation of cellular adhesion molecules through progesterone B receptors. Cancer Res 62:881–886. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/11830547
5. Smid-Koopman E, Blok LJ, Kühne LCM, Burger CW, Helmerhorst TJM, Brinkmann AO et al (2003) Distinct functional differences of human progesterone receptors A and B on gene expression and growth regulation in two endometrial carcinoma cell lines. J Soc Gynecol Invest 10:49–57. Retrieved from
http://www.ncbi.nlm.nih.gov/pubmed/12517594
. Accessed on 18 Aug 2017